Table 2. Antigens upregulated in metastasis.
| Antigen | Cell line (% Positivity) | ||
| SW480 | SW620 | SW620/SW480 ratio | |
| CD10/MME | 18.49 | 93.61 | +5.06 |
| CD119/IFNγR1 * | 10.45 | 40.84 | +3.91 |
| CD4 | 21.44 | 69.40 | +3.24 |
| CD109 * | 20.92 | 64.00 | +3.06 |
| CD43 | 30.01 | 91.96 | +3.06 |
| CLA | 17.80 | 52.50 | +2.95 |
| CD205 * | 11.42 | 32.24 | +2.82 |
| CD227/MUC-1 | 30.20 | 82.76 | +2.75 |
| CD4v4 * | 20.85 | 55.46 | +2.65 |
| CD24 | 36.73 | 91.06 | +2.48 |
| CD99 | 40.63 | 92.11 | +2.27 |
Antibody array results showing surface antigens that were at least two-fold increased in cell positivity in SW620 (metastatic) as compared to SW480 (primary). Abbreviations: membrane metallo-endopeptidase, MME; cutaneous lymphocyte antigen, CLA; mucin 1, MUC-1.
*
, Antigen was not two-fold increased by comparison of mean fluorescence intensities; however, differences in autofluorescence between cell lines limited the applicability of this analysis (Table S4).